Remedy Robotics and the Society of Vascular and Interventional Neurology’s (SVIN) Mission Thrombectomy have announced a strategic partnership to expand access to stroke thrombectomy in the USA and worldwide using Remedy’s N1 system.
Through this partnership, Remedy will become Mission Thrombectomy’s exclusive robotics partner and work in close collaboration with its world-leading clinical network—which includes regional committees in more than 100 countries—and the broader SVIN network to test, develop and guide the global rollout of Remedy’s telerobotic technology into stroke thrombectomy workflows.
“We are thrilled that Mission Thrombectomy has selected Remedy Robotics as its exclusive robotics partner to expand access to endovascular thrombectomy for stroke patients both in the USA and worldwide,” said David Bell, chief executive officer (CEO) and co-founder of the company. “This collaboration will advance our shared vision of making the best endovascular intervention available to patients, wherever they are. Working with Mission Thrombectomy’s world-class clinicians and global network, we will make endovascular thrombectomy safer and more equitably accessible to patients across the USA and the world.”
This partnership builds on Mission Thrombectomy’s proven leadership in research, clinician training, guideline development and global advocacy for endovascular thrombectomy, a press release notes, adding that the two organisations will work to accelerate the deployment of Remedy’s N1 system with the goal of expanding access to thrombectomy—particularly in underserved regions.
“No patient’s chance of recovery should depend on their ZIP code,” commented Fawaz Al-Mufti (New York Medical College, New York, USA), global chair of Mission Thrombectomy. “At Mission Thrombectomy, our goal is to ensure that the life-saving benefits of endovascular thrombectomy are available to patients worldwide without delay. By combining our clinical network, training programmes and global advocacy reach with Remedy’s groundbreaking telerobotic technology, we can dramatically expand access to this life-saving treatment.”
The previously published MT-GLASS study—led by Mission Thrombectomy—found that only one third of Americans have access to endovascular thrombectomy without delay. However, this availability is still significantly higher compared to in low-income countries, where the mean access rate is less than 1%. Overall, fewer than 3% of the global population has access to this care. According to Remedy, these figures underscore the urgent need for a scalable, reliable solution, in the company’s N1 system, to make safe and effective thrombectomy available to patients everywhere.
“Access to thrombectomy is dismally low globally, despite it being a brain-saving, disability-sparing and life-saving therapy. More than 97% of patients are being left untreated,” stated Dileep Yavagal (University of Miami, Coral Gables, USA), founder and global chair-emeritus of Mission Thrombectomy. “Remedy Robotics’ technology offers a powerful new avenue to solve this challenge by allowing clinicians to provide the best care remotely to patients immediately, wherever they are in the world. We are excited that Remedy has chosen to partner with Mission Thrombectomy, and to work with them as we continue to champion national and worldwide access to thrombectomy.”
